| Field | Specification |
|---|---|
| Target | |
| Alternative names | Keratin, type II cytoskeletal 7; Cytokeratin-7; CK-7; Keratin-7; K7; Sarcolectin; Type-II keratin Kb7; KRT7; SCL |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human KRT7, which shares 91.3% amino acid (aa) sequence identity with mouse and rat KRT7. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets keratin, type II cytoskeletal 7 (gene KRT7) in human samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 51.4 kDa, and the supplier reports an observed band at about 51 kDa.
Keratin 7 (KRT7) is a type II intermediate filament protein of simple and glandular epithelia, including ducts of the lung, breast and urinary tract. It is absent from most gastrointestinal epithelium, which makes the combined staining of keratin 7 and keratin 20 a common tool for classifying carcinomas in pathology research.
| Target | Keratin, type II cytoskeletal 7 (gene KRT7; UniProt P08729, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 51.4 kDa |
| Observed MW | 51 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | Not specified by the supplier |
Samples with a confirmed band (WB): human HeLa cells, human RT4 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human breast cancer tissue, human thyroid cancer tissue, human placenta tissue, human stomach cancer tissue, human lung cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): human throid cancer tissue, human stomach cancer tissue, human lung cancer tissue, human breast cancer tissue, human ovarian cancer tissue.
Immunogen
Synthetic peptide from the middle region of human KRT7. Sequence identity with the mouse and rat orthologs: 91.3%.
Reactivity Notes
The supplier lists reactivity with human. UniProt places keratin, type II cytoskeletal 7 in the cytoplasm. Tissue expression noted by UniProt (human): Expressed in cultured epidermal, bronchial and mesothelial cells but absent in colon, ectocervix and liver. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Haichuan Liu et al. (2023) Necroptosis-Related Prognostic Model for Pancreatic Carcinoma Reveals Its Invasion and Metastasis Potential through Hybrid EMT and Immune Escape. Biomedicines. 10.3390/biomedicines11061738
Yuan Qiao et al. (2020) Infection of Placental Extravillous Cytotrophoblasts with Human Cytomegalovirus Causes a Treg/Th17 Imbalance at the Maternal–Fetal Interface. Cell Transplantation. 10.1177/0963689720925055
Li Qiang et al. (2013) All-trans retinoic acid inhibits craniopharyngioma cell growth: study on an explant cell model. Journal of Neuro-Oncology. 10.1007/s11060-013-1080-z
Luo Hai-Tao et al. (2017) Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer. Bioscience Reports. 10.1042/BSR20171086
Wang Yuelong et al. (2016) Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma. Journal of Neuro-Oncology. 10.1007/s11060-016-2273-z
Q. Luo et al. (2015) Ephrin-B2 mediates trophoblast-dependent maternal spiral artery remodeling in first trimester. Placenta. 10.1016/j.placenta.2015.02.009
Q.-j. Wang et al. (2015) Expression of RGC32 in human normal and preeclamptic placentas and its role in trophoblast cell invasion and migration. Placenta. 10.1016/j.placenta.2014.12.012
Hui Tao et al. (2019) LncRNA MEG3 inhibits trophoblast invasion and trophoblast-mediated VSMC loss in uterine spiral artery remodeling. Molecular Reproduction and Development. 10.1002/mrd.23147
Hongchuan Tan et al. (2019) Is Atrial Natriuretic Peptide (ANP) and Natriuretic Peptide Receptor-A (NPR-A) Expression in Human Placenta and Decidua Normal?. Medical Science Monitor. 10.12659/MSM.915449
